Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioNumerik
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: South Korea, Taiwan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Adenocarcinoma|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2061240024 | P2 |
Recruiting |
Adenocarcinoma |
2026-08-31 |
|
| HARMONIC | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2025-12-01 |